FOLH1 and prostate carcinoma: Nevertheless, with the advent of the radiotherapeutic PSMA derivatives, the question of the future clinical utility of these bone-seeking agents for the management of metastatic prostate cancers arises, though its interest remains for bone metastases arising from other tumors, such as breast or lung carcinomas.